We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
09/9/2020 09:18 | Yes monty: GSK Consumer Healthcare (LSE/NYSE: GSK) today announced the launch of new Advil Dual Action, an exclusive formula that combines two of the most powerful pain fighting ingredients: ibuprofen and acetaminophen. | tradermichael | |
09/9/2020 09:16 | Yes good news keeps coming.https://www.p | montyhedge | |
09/9/2020 09:07 | If first and they are up there, worth billions worldwide. | montyhedge | |
09/9/2020 09:05 | It is profit making, it will be each year just like the flu jab at 9 pound a pop. | montyhedge | |
09/9/2020 09:03 | aahh ok Thanks TM | nico9 | |
09/9/2020 08:56 | nico9 - the share price 'slump' isn't about lost potential from a "non-profit" making drug, its about the lost investment already committed. | tradermichael | |
09/9/2020 08:55 | GSK Consumer Healthcare Introduces the Biggest Innovation in the U.S. Over-The-Counter Oral Pain Relief Category in 25 Years:...Source: PR Newswire (US)WARREN, N.J., Sept. 8, 2020 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) today announced the launch of new Advil Dual Action, an exclusive formula that combines two of the most powerful pain fighting ingredients: ibuprofen and acetaminophen. In February, the Food and Drug Administration (FDA) approved Advil Dual Action as the first and only over-the-counter medication that combines ibuprofen and acetaminophen. The widely used, effective ingredients help to manage pain in two ways: ibuprofen works through the body, targeting pain at the source, while acetaminophen blocks pain signals to the brain. The innovation takes these two powerful pain fighting ingredients and combines them into one tablet to offer fast, strong pain relief.spud | spud | |
09/9/2020 08:29 | GSK surely going to win this race now Astra has fallen at the last fence. | montyhedge | |
09/9/2020 08:02 | Sanofi/GSK more experienced in vaccines in my opinion.If GSK first, easily over 2150p. Astra has stumble. | montyhedge | |
09/9/2020 07:33 | Astra seems problem with Coronavirus vaccine trial.GSK must be in the lead now.https://www.dail | montyhedge | |
09/9/2020 07:11 | 6% is quite a slump in share price for a drug that is meant to be a No Profit drug. Glad its not GSK based on the price we are at the moment!! Big drop generally in US so could well be another drop on opening | nico9 | |
08/9/2020 22:59 | AstraZeneca shares fell more than 6% in after-hours trading Tuesday after the company said its late-stage trial for a potential coronavirus vaccine had been put on hold due to safety concerns. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials, In large trials illnesses will happen by chance but must be independently reviewed to check this carefully," the company said in a statement to CNBC. It said it was trying to expedite the review to "minimize any potential impact on the trial timeline."CNBC's Meg Tirrell contributed to this report. spud | spud | |
08/9/2020 18:26 | Boost for Oxford Covid vaccine as it emerges rivals' must be 'deep frozen' at -70C | zho | |
08/9/2020 18:24 | You will take whichever one you are told to comrade! :) | geckotheglorious | |
08/9/2020 18:21 | Would take a vaccine by the Russians or Astra, Sanofi/GSK.I think I know the answer. | montyhedge | |
08/9/2020 17:34 | FX a far bigger factor, as we've just seen than any vaccine. | essentialinvestor | |
08/9/2020 17:24 | In a bombshell accusation that calls China's COVID-19 numbers into question, South Korea reported that five passengers arriving in South Korea from China have been tested positive for coronavirus since Aug. 16. Among the five, two were South Korean citizens and three were Chinese nationals. All showed no symptoms. However, in a major speech on Tuesday, President Xi insisted that Chinese data were accurate. "Does anyone actually believe the Chinese timeline of events? Or their current infection/fatality rates!" | geckotheglorious | |
08/9/2020 17:22 | Could all be beaten by the Russkies...... In Russia, another vaccine could be on its way to government approval, with Siberia's Vector virology institute completing Phase II, which involves roughly 100 human volunteer test subjects, which suggests the vaccine is safe. Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute, back in August, and is currently aiming to finish up Phase 3 testing by the beginning of November. The final round of trials, involving some 40,000 participants around the world, were launched last week, and on Tuesday. Russia reported 5,099 new coronavirus cases , pushing its national tally to 1,035,789, the fourth largest in the world. Authorities confirmed 122 deaths in the last 24 hours, bringing the official death toll to 17,993. | geckotheglorious | |
08/9/2020 15:30 | Yes Joe Public, plus the pharma's vaccine will be given each year, just like the flu value and at 9 pound a pop. | montyhedge | |
08/9/2020 14:13 | If there is more than one vaccine then it is us, Joe Public, who are the winners. | alphorn | |
08/9/2020 14:11 | My money on Pfizer myself. Pfizer (NYSE:PFE) development partner BioNTech (NASDAQ:BNTX) announces regulatory sign-off in Germany for its Phase 2/3 clinical trial evaluating COVID-19 vaccine candidate BNT162b2. The companies say more than 25K participants have been enrolled thus far, 83% of the target of 30K across 120 sites globally. | geckotheglorious | |
08/9/2020 11:48 | Sanofi/GSK have more experience in vaccines in my opinion. Astra great oncology. | montyhedge | |
08/9/2020 11:24 | AZN have too much of a jump start imo. spud | spud | |
08/9/2020 11:06 | If first shares over 2100p easily. They will be share of the year 2021. Plus dividend every 13 weeks on the doormat. Come on Sanofi/Gsk you can do it. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions